CompletedPhase 2NCT04956666

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institut de Recherches Internationales Servier
Principal Investigator
Alexander Isaakovich Karachunskiy, PhD
Director of Institute of Oncology, Radiology and Nuclear Medicine. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Intervention
Lyophilized S95014(drug)
Enrollment
75 enrolled
Eligibility
1-17 years · All sexes
Timeline
20212023

Study locations (6)

Collaborators

ADIR, a Servier Group company · Les Laboratoires Servier (L.L.S), Russia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04956666 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials